PeptideStack
5.2kquestions
20kanswers
220users

What happens to tirzepatide after ten weeks at minus 80 °C in solution?

Asked 30 Jul 2025Modified 9 months agoViewed 16k times
33

For reference: tirzepatide · ten weeks · minus 80 °C.

I would like the mechanism, because I want to be able to reason about the cases nobody has written about.

I have tried to reason it out from first principles and got to two contradictory conclusions.

Can someone derive this rather than assert it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
MT
askedmarcus_thorbjorn9.4k1630 Jul 2025

4 Answers

Accepted answer first, then by votes
89

Accepted answer

ten weeks is 70 days at a temperature where the chemistry all but stops and the physics does not. minus 80 °C is 85 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. In a frozen solution the solute is excluded from the growing ice, so the unfrozen fraction concentrates and the buffer's pH moves as one salt crystallises before the other. The damage is done at the transitions, and 70 days of stable hold between them contributes very little. Reconstituted material has no certificate; the one in the box describes the powder.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Stated carefully, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
TV
answered · acceptedten_mg_vial31k1384 Nov 2025
3The doubling-per-ten-degrees rule is the part I did not know and now use constantly. – triple_agonist_q 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
36

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
TR
answeredtobias_reint20k3824 Oct 2025
3Confirming that opening a cold vial in a humid room is a genuinely bad idea. – ekaterina_volk 2 months ago
2This should be in the site help pages rather than buried in an answer. – j_wierzbicki 3 days ago
add a comment
25

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

The relevant detail is that oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Cold, dry, dark, still. Those four words cover most of the mitigation.

edited 27 Oct 2025 by h_pergande — tightened the wording; no substantive change

shareimprove this answerflag
HP
answeredh_pergande71k15813 Oct 2025
21

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
GA
answeredgrainne_ahearn50k382 Oct 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.